THERAPY DOSSIER · th-b4f47a434103

DPCPX (8-cyclopentyl-1,3-dipropylxanthine)

Drug · DPCPX (8-cyclopentyl-1,3-dipropylxanthine), a selective adenosine A1 receptor antagonist (tool compound).

Evidence & regulatory context

Mechanism: DPCPX (8-cyclopentyl-1,3-dipropylxanthine), a selective adenosine A1 receptor antagonist (tool compound).
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31600096 ↗2019Reported benefit

Sleep disordered breathing induced by cervical spinal cord injury and effect of adenosine A1 receptors modulation in rats.

RatSpinal cord injuryHemisection / partialSprague-DawleyMaleOral

Model: Left hemisection of the second cervical spinal cord segment (C2Hx), with sham laminectomy as control; breathing assessed at acute (about 1 week) and chronic (about 6 weeks) time points

C2 hemisection raised the apnoea-hypopnoea index relative to sham (35.5 plus or minus 12.6 versus 19.1 plus or minus 2.1 events per hour, p less than 0.001). Oral DPCPX significantly reduced the apnoea-hypopnoea index four days after treatment compared with placebo (69.5 plus or minus 8.9 per cent…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…